Lamivudine 300 MG Oral Tablet [Epivir] — RxCUI 352230
RxNorm drug concept · Semantic branded drug
RxCUI 352230
Semantic branded drug · SBD
● Current RxNorm concept 3 FDA products
3 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI352230
Official nameLamivudine 300 MG Oral Tablet [Epivir]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asEpivir 300 MG Oral Tablet; 3TC 300 MG Oral Tablet [Epivir]
FDA products mapped3
Package NDCs mapped3
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Lamivudine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Lamivudine treats HIV-1 infection when combined with other HIV medicines. A separate lower-dose tablet treats chronic hepatitis B. Make sure you have the version your doctor prescr...
- For HIV-1 it is taken by mouth once or twice daily, with or without food. Follow your prescriber's schedule exactly. Children's doses depend on weight.
- Common ones are headache, nausea, tiredness, stuffy nose, diarrhea and cough. Call your doctor if you notice signs of liver problems, pancreatitis, or an allergic reaction.
- Please don't stop on your own. If you also have hepatitis B, stopping can cause a serious flare-up, and your liver needs close monitoring afterward. Talk to your doctor first.
🕸️ Concept Web — How Lamivudine 300 MG Oral Tablet [Epivir] Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Lamivudine 300 MG Oral Tablet [Epivir]
RxCUI 352230 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Lamivudine
68244IN
-
Lamivudine
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Epivir
196478BN
-
Epivir
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Lamivudine Oral Tablet
372563SCDF -
Lamivudine Oral Product
1162819SCDG -
Lamivudine Pill
1162820SCDG -
Lamivudine Oral Tablet [Epivir]
367794SBDF -
Epivir Oral Product
1167630SBDG -
Epivir Pill
1167631SBDG -
Oral Tablet
317541DF -
Oral Product
1151131DFG - +1 more in this family
-
Lamivudine Oral Tablet
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Lamivudine 300 MG Oral Tablet
349491SCD -
Lamivudine 300 MG
350655SCDC -
Lamivudine 300 MG [Epivir]
575950SBDC
-
Lamivudine 300 MG Oral Tablet
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Lamivudine 300 MG Oral Tablet
SCD · 349491 -
Lamivudine 300 MG
SCDC · 350655 -
Lamivudine Oral Tablet
SCDF · 372563 -
Lamivudine Oral Product
SCDG · 1162819 -
Lamivudine Pill
SCDG · 1162820
Brand-Name Concepts
-
Lamivudine 300 MG [Epivir]
SBDC · 575950 -
Lamivudine Oral Tablet [Epivir]
SBDF · 367794 -
Epivir Oral Product
SBDG · 1167630 -
Epivir Pill
SBDG · 1167631 -
Epivir
BN · 196478
📦 FDA Products & Package NDCs
3 products · 3 package NDCs
3 package NDCs map to RxCUI 352230 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 49702-0203-18 | 60 TABLET, FILM COATED in 1 BOTTLE (49702-203-18) | EPIVIR | ViiV Healthcare Company | 2010-10-04 |
| 49702-0204-13 | 30 TABLET, FILM COATED in 1 BOTTLE (49702-204-13) | EPIVIR | ViiV Healthcare Company | 2010-10-04 |
| 49702-0205-48 | 240 mL in 1 BOTTLE (49702-205-48) | EPIVIR | ViiV Healthcare Company | 2010-10-04 |
Observed labelers:
ViiV Healthcare Company (3)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.